Latest & greatest articles for migraine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on migraine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on migraine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for migraine

1. Acupuncture for migraine headaches

Acupuncture for migraine headaches Acupuncture for migraine headaches Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Acupuncture for migraine headaches View/ Open Date 2010-04 Format Metadata Abstract Acupuncture reduces the frequency of migraine headaches when used as an adjunct to, or in place of, medical management

2019 Clinical Inquiries

2. Erenumab (Aimovig) - Migraine

Erenumab (Aimovig) - Migraine erenumab | CADTH.ca Find the information you need erenumab erenumab Last Updated: October 3, 2019 Result type: Reports Project Number: SR0578-000 Product Line: Generic Name: erenumab Brand Name: Aimovig Manufacturer: Novartis Pharmaceuticals Canada Inc. Indications: Migraine Manufacturer Requested Reimbursement Criteria 1 : For prevention of migraine in adults who have at least 8 migraine days per month and who have previously failed, are intolerant, or have (...) a contraindication to at least two migraine preventive therapies Submission Type: New Project Status: Active Biosimilar: No Fee Schedule: Schedule A The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable. Key Milestones 2 Call for patient input posted April 04, 2019 Clarification: CADTH initially posted the call for patient from July 12, 2018 to August 31

2019 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

3. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. (PubMed)

Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Antibodies targeting calcitonin gene-related peptide (CGRP) or its receptor have shown efficacy in the prevention of migraine attacks. We investigated the efficacy and tolerability of fremanezumab, a fully humanised CGRP antibody, in patients with migraine who had previously (...) not responded to two to four classes of migraine preventive medications.The randomised, double-blind, placebo-controlled, parallel-group, phase 3b FOCUS trial was done at 104 sites (including hospitals, medical centres, research institutes, and group practice clinics) across Belgium, the Czech Republic, Denmark, Finland, France, Germany, Italy, the Netherlands, Poland, Spain, Sweden, Switzerland, the UK, and the USA. We enrolled participants aged 18-70 years with episodic or chronic migraine who had

2019 Lancet Controlled trial quality: predicted high

4. Practice guideline update summary: Acute treatment of migraine in children and adolescents: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society

Practice guideline update summary: Acute treatment of migraine in children and adolescents: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society To provide evidence-based recommendations for the acute symptomatic treatment of children and adolescents with migraine.We performed a systematic review of the literature and rated risk of bias of included studies according to the American Academy (...) , acetaminophen (in children and adolescents), and triptans (mainly in adolescents) for the relief of migraine pain, although confidence in the evidence varies between agents. There is high confidence that adolescents receiving oral sumatriptan/naproxen and zolmitriptan nasal spray are more likely to be headache-free at 2 hours than those receiving placebo. No acute treatments were effective for migraine-related nausea or vomiting; some triptans were effective for migraine-related phonophobia

Full Text available with Trip Pro

2019 EvidenceUpdates

5. Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society

Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society To provide updated evidence-based recommendations for migraine prevention using pharmacologic treatment with or without cognitive behavioral therapy in the pediatric population.The authors systematically reviewed literature from January 2003 (...) to August 2017 and developed practice recommendations using the American Academy of Neurology 2011 process, as amended.Fifteen Class I-III studies on migraine prevention in children and adolescents met inclusion criteria. There is insufficient evidence to determine if children and adolescents receiving divalproex, onabotulinumtoxinA, amitriptyline, nimodipine, or flunarizine are more or less likely than those receiving placebo to have a reduction in headache frequency. Children with migraine receiving

Full Text available with Trip Pro

2019 EvidenceUpdates

6. Erenumab (Aimovig) for the prevention of migraine attacks: decrease in the frequency of attacks in some patients, but uncertainty over cardiovascular effects

Erenumab (Aimovig) for the prevention of migraine attacks: decrease in the frequency of attacks in some patients, but uncertainty over cardiovascular effects Prescrire IN ENGLISH - Spotlight ''Erenumab (Aimovig°) for the prevention of migraine attacks: decrease in the frequency of attacks in some patients, but uncertainty over cardiovascular effects '', 1 September 2019 {1} {1} {1} | | Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |    (...) |   |   |   |   |   |   |  Spotlight Erenumab (Aimovig°) for the prevention of migraine attacks: decrease in the frequency of attacks in some patients, but uncertainty over cardiovascular effects FEATURED REVIEW Erenumab (Aimovig°) is a monoclonal antibody that has been authorised in the European Union for the prevention of migraine attacks in patients who experience attacks on more than 4 days a month. Prescrire's editorial staff have weighed

2019 Prescrire

7. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. (PubMed)

Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Rimegepant, a small molecule calcitonin gene-related peptide receptor antagonist, has shown efficacy in the acute treatment of migraine using a standard tablet formulation. The objective of this trial was to compare the efficacy, safety, and tolerability of a novel orally disintegrating tablet formulation of rimegepant (...) at 75 mg with placebo in the acute treatment of migraine.In this double-blind, randomised, placebo-controlled, multicentre phase 3 trial, adults aged 18 years or older with history of migraine of at least 1 year were recruited to 69 study centres in the USA. Participants were randomly assigned to receive rimegepant (75 mg orally disintegrating tablet) or placebo and instructed to treat a single migraine attack of moderate or severe pain intensity. The randomisation was stratified by the use

2019 Lancet Controlled trial quality: predicted high

8. Pharmacologic Treatment for Pediatric Migraine Prevention

Pharmacologic Treatment for Pediatric Migraine Prevention 1 Practice guideline update: 1 Pharmacologic treatment for pediatric migraine prevention 2 Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the 3 American Academy of Neurology and the American Headache Society 4 Authors 5 Maryam Oskoui, MD, MSc, 1 Tamara Pringsheim, MD, 2 Lori Billinghurst MD, 3 Sonja Potrebic, 6 MD, PhD, 4 Elaine M. Gersz, 5 David Gloss, MD, MPH&TM, 6 Yolanda Holler-Managan, MD, 7 7 (...) with Episodic or Chronic Migraine: Effectiveness and Value Final Evidence Report. 2 3 L. Billinghurst has no relevant disclosures for this guideline. D. Gloss has no relevant disclosures 4 for this guideline. 5 A. Hershey has served on a scientific advisory board for Allergan, XOC Pharma, and Amgen; 6 served as an editor for Headache, Cephalalgia, and the Journal of Headache and Pain; has 7 received compensation from Allergan and MAP Pharma and currently receives compensation 8 from Alder, Amgen, Avanir

2019 American Academy of Neurology

9. Acute Treatment of Migraine in Children and Adolescents

Acute Treatment of Migraine in Children and Adolescents 1 Practice guideline update: Acute treatment of migraine in children and adolescents 1 Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the 2 American Academy of Neurology and the American Headache Society 3 4 Maryam Oskoui, MD, MSc, 1 Tamara Pringsheim, MD, 2 Yolanda Holler-Managan, MD, 3 Sonja 5 Potrebic, MD, PhD, 4 Lori Billinghurst MD, MSc, 5 David Gloss, MD, 6 Andrew D. Hershey, MD, 6 PhD, 7 (...) Treatments for Patients with Episodic or Chronic Migraine: Effectiveness and Value 17 Final Evidence Report. 18 L. Billinghurst has no relevant disclosures for this guideline. 19 D. Gloss has no relevant disclosures for this guideline. 20 6 A. Hershey has served on a scientific advisory board for Allergan, XOC Pharma, and Amgen; 1 served as an editor for Headache, Cephalalgia, and the Journal of Headache and Pain; has 2 received compensation from Allergan and MAP Pharma and currently receives

2019 American Academy of Neurology

10. Two randomized migraine studies of galcanezumab: Effects on patient functioning and disability

Two randomized migraine studies of galcanezumab: Effects on patient functioning and disability To evaluate changes from baseline in patient-reported outcomes for measures of functioning and disability among patients with migraine treated with galcanezumab or placebo.Patients with episodic migraine (4-14 monthly migraine headache days) were treated with either galcanezumab (Evaluation of LY2951742 in the Prevention of Episodic Migraine [EVOLVE]-1: 120 mg n = 210, 240 mg n = 208; EVOLVE-2: 120 mg (...) n = 226, 240 mg n = 220) or placebo (EVOLVE-1 n = 425; EVOLVE-2 n = 450) during 6 months of treatment. Migraine-Specific Quality of Life Questionnaire v2.1 (MSQv2.1) measured the effect of migraine on patient functioning (physical and emotional) in 3 domains, and the Migraine Disability Assessment (MIDAS) quantified headache-related disability associated with missed or reduced productivity at work or home and social events. Both were collected at baseline and during the treatment period (MSQv2.1

Full Text available with Trip Pro

2019 EvidenceUpdates

11. Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine. (PubMed)

Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine. Calcitonin gene-related peptide receptor has been implicated in the pathogenesis of migraine. Rimegepant is an orally administered, small-molecule, calcitonin gene-related peptide receptor antagonist that may be effective in acute migraine treatment.In a multicenter, double-blind, phase 3 trial, we randomly assigned adults with at least a 1-year history of migraine and two to eight migraine attacks (...) of moderate or severe intensity per month to receive rimegepant orally at a dose of 75 mg or matching placebo for the treatment of a single migraine attack. The primary end points were freedom from pain and freedom from the most bothersome symptom (other than pain) identified by the patient, both of which were assessed 2 hours after the dose of rimegepant or placebo was administered.A total of 1186 patients were randomly assigned to receive rimegepant (594 patients) or placebo (592 patients

2019 NEJM Controlled trial quality: predicted high

12. Psychological therapies for the prevention of migraine in adults. (PubMed)

Psychological therapies for the prevention of migraine in adults. Migraine is a common neurological problem associated with the highest burden amongst neurological conditions in terms of years lived with disability. Medications can be used as prophylaxis or rescue medicines, but are costly and not always effective. A range of psychological interventions have been developed to manage migraine.The objective was to evaluate the efficacy and adverse events of psychological therapies (...) for the prevention of migraine in adults.We searched CENTRAL, MEDLINE, Embase, PsycINFO and CINAHL from their inception until July 2018, and trials registries in the UK, USA, Australia and New Zealand for randomised controlled trials of any psychological intervention for adults with migraine.We included randomised controlled trials (RCTs) of a psychological therapy for people with chronic or episodic migraine, with or without aura. Interventions could be compared to another active treatment (psychological

2019 Cochrane

13. Toxins for Health? Botulinum toxin for migraine

Toxins for Health? Botulinum toxin for migraine Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,800 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research. www.acfp.ca May 13, 2019 Toxins (...) for Health? Botulinum toxin for migraine. Clinical Question: What is the efficacy of botulinum toxin for migraine prophylaxis? Bottom Line: Patients with chronic migraine who receive botulinum toxin (example Botox™) have 2 fewer migraine days per month compared to placebo (from 19 days to 11 days with treatment versus 13 days with placebo), with no benefit in episodic migraine. Adverse events include blepharoptosis, muscle weakness, neck/injection site pain and 3% stop treatment due to adverse events

2019 Tools for Practice

14. Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study

Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study To determine the effect of erenumab, a human monoclonal antibody targeting the calcitonin gene-related peptide receptor, on health-related quality of life (HRQoL), headache impact, and disability in patients with chronic migraine (CM).In this double-blind, placebo-controlled study, 667 adults with CM were randomized (3:2:2) to placebo or erenumab (70 or 140 mg monthly). Exploratory endpoints included (...) migraine-specific HRQoL (Migraine-Specific Quality-of-Life Questionnaire [MSQ]), headache impact (Headache Impact Test-6 [HIT-6]), migraine-related disability (Migraine Disability Assessment [MIDAS] test), and pain interference (Patient-Reported Outcomes Measurement Information System [PROMIS] Pain Interference Scale short form 6b).Improvements were observed for all endpoints in both erenumab groups at month 3, with greater changes relative to placebo observed at month 1 for many outcomes. All 3 MSQ

2019 EvidenceUpdates

15. Comparison of two ultrasound-guided techniques for greater occipital nerve injections in chronic migraine: a double-blind, randomized, controlled trial

Comparison of two ultrasound-guided techniques for greater occipital nerve injections in chronic migraine: a double-blind, randomized, controlled trial Two ultrasound (US)-guided techniques for greater occipital nerve (GON) block have been described for the management of headache disorders: a "proximal or central" technique targeting the GON at the level of the second cervical vertebra and a "distal or peripheral" technique targeting the GON at the level of the superior nuchal line (...) . In this multicenter, prospective, randomized control trial, we compared accuracy, effectiveness, and safety of these two techniques in patients with chronic migraines (CMs).Forty patients with refractory CMs were randomized to receive either a proximal or distal US-guided GON block with bupivacaine and methylprednisolone acetate. The primary outcome was the difference in Numerical Rating Score (NRS) for headache intensity at 1 month. Secondary outcomes were effectiveness, performance, and safety-related

2019 EvidenceUpdates

16. Erenumab (Aimovig) - for the prophylaxis of migraine

Erenumab (Aimovig) - for the prophylaxis of migraine 1 Published 08 April 2019 1 SMC2134 erenumab 70mg solution for injection in pre-filled pen (Aimovig®) Novartis Pharmaceuticals UK Ltd 8 March 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission erenumab (Aimovig ® ) is accepted (...) for restricted use within NHSScotland. Indication under review: for the prophylaxis of migraine in adults who have at least four migraine days per month. SMC restriction: patients with chronic migraine and in whom at least three prior prophylactic treatments have failed. In studies in patients with episodic and chronic migraine, erenumab significantly reduced the number of migraine days per month compared with placebo. This SMC advice takes account of the benefits of a Patient Access Scheme (PAS

2019 Scottish Medicines Consortium

17. Fremanezumab (Ajovy) - migraine

Fremanezumab (Ajovy) - migraine Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. EMA/107467/2019 EMEA/H/C/004833 Ajovy (fremanezumab) An overview of Ajovy and why it is authorised (...) in the EU What is Ajovy and what is it used for? Ajovy is a medicine used to prevent migraine in adults who have migraines at least 4 days a month. The active substance contained in Ajovy is fremanezumab. How is Ajovy used? Ajovy is injected under the skin using a pre-filled syringe. Patients can inject the medicine themselves after being trained. The recommended dose is either 225 mg every month or 675 mg every three months. For the 675 mg dose, three injections of 225 mg have to be injected one after

2019 European Medicines Agency - EPARs

18. Acupuncture for migraine headaches

Acupuncture for migraine headaches Acupuncture for migraine headaches Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Acupuncture for migraine headaches View/ Open Date 2010-04 Format Metadata Abstract Acupuncture reduces the frequency of migraine headaches when used as an adjunct to, or in place of, medical management

2019 Clinical Inquiries

19. Intravenous Fluid for the Treatment of Emergency Department Patients With Migraine Headache: A Randomized Controlled Trial

Intravenous Fluid for the Treatment of Emergency Department Patients With Migraine Headache: A Randomized Controlled Trial The objective of this pilot study is to assess the feasibility and necessity of performing a large-scale trial to measure the effect of intravenous fluid therapy on migraine headache pain.This was a single-center, pilot randomized controlled trial. We randomized adult emergency department migraine headache patients to receive 1 L of normal saline solution during 1 hour

2019 EvidenceUpdates

20. Acupuncture shows promise for preventing episodic migraines

Acupuncture shows promise for preventing episodic migraines Acupuncture shows promise for preventing episodic migraines Discover Portal Discover Portal Acupuncture shows promise for preventing episodic migraines Published on 18 October 2016 doi: Acupuncture was about as effective as long term medication in reducing the number of migraines. There were fewer adverse events amongst people receiving acupuncture (16-17%) compared to drug treatment (34%). Migraines affect around one in seven people (...) to people living in certain areas or who can afford to pay for treatment themselves. Share your views on the research. Why was this study needed? Migraines are common, affecting around one in five women and one in 15 men. Symptoms include headache, visual disturbances and nausea, which can be severe enough to stop people living their normal daily life. Migraine attacks last anywhere between four and 72 hours and are estimated to cost the UK economy as much as £2 billion a year in lost work. The cause

2019 NIHR Dissemination Centre